Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7557084 | 1.00 | PARP1 (0.55) | PARP1HDAC4IGF1RSCDGSK3B | |
| SCHEMBL7557691 | 0.91 | PARP1 (0.53) | PARP1HDAC4IGF1RSCDKDM4E | |
| SCHEMBL7557694 | 0.91 | PARP1 (0.53) | PARP1HDAC4IGF1RSCDKDM4E | |
| SCHEMBL7553262 | 0.89 | PARP1 (0.56) | PARP1HDAC4SCD | |
| SCHEMBL7553257 | 0.89 | PARP1 (0.56) | PARP1HDAC4SCD | |
| SCHEMBL7556496 | 0.88 | GSK3B (0.47) | PARP1HDAC4GSK3BKDM4EMAPT | |
| SCHEMBL7556489 | 0.88 | GSK3B (0.47) | PARP1HDAC4GSK3BKDM4EMAPT | |
| SCHEMBL7559210 | 0.84 | PARP1 (0.60) | PARP1IGF1RGSK3BPOLH | |
| SCHEMBL7559216 | 0.84 | PARP1 (0.60) | PARP1IGF1RGSK3BPOLH | |
| SCHEMBL7554789 | 0.81 | GSK3B (0.63) | PARP1IGF1RGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | CHIN ALLISON C (US) | 2002-08-22 | — | — | US | disclosed |
| US-6372742-B1 | TELOMERASE ENZYME INHIBITORS AND ANTICANCER AGENTS | GERON CORPORATION | 2002-04-16 | — | — | US | disclosed |
| EP-1109808-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002394-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115700-A1 | Substituted indole compounds and methods of their use | TERT, INMT, POT1 | PARP1 76/4885HDAC4 587/4885IGF1R 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.